New York, October 25th, 2018- Creative Biolabs, a world leader in the genetic engineering and biotechnology field, has announced a great achievement of antibody-drug conjugates (ADCs) in the suitable linker and efficient drug conjugation. Creative Biolabs has worked on antibody design and modification to fit various bio-conjugation strategies.
Antibody drug conjugate (ADC) combines the antitumor activity of mAbs with the cell killing of small molecule drugs. The most important step in the development of ADCs is designing of suitable linkers to make sure of the stable and efficient delivery of the cytotoxic drug to the target cells. Thus, selecting the right antibody-drug linkage is critical to optimizing the therapeutic efficacy and tolerability of ADCs. Linker design for ADCs is highly dependent on the biology of the target cells, the characteristics of the antibody, and the structure of the drug molecule. Creative Biolabs gives a way to achieve an ideal linker, which can possess exceeding stability in systemic circulation, and readily release the cytotoxic payload in its active form upon reaching the target site. The company has developed professional ADC linker design and drug-linker complex synthesis services, including cleavable linkers, which rely on the inherent properties of a cell’s cytoplasmic compartments for selective release of the cytotoxic drug and non-cleavable linkers.
There’s no denying that the design of a chemically compatible antibody for the conjugation chemistry largely determines the fate of an ADC project. The antibody, one of the major components of an ADC, serves as the cargo to deliver the cytotoxic drug, which is the key to target specificity. Potential conjugation sites can be attached by multiple endogenous amino acids. However, Creative Biolabs has achieved more precisely controlled site-directed drug conjugations and subsequently a narrower distribution of drug-to-antibody ratio (DAR). In order to gain a narrower DAR, Creative Biolabs has explored and adopted a variety of methodologies in antibody design and engineering to insert a series of specific and chemically versatile conjugation sites into the antibody sequences. In the antibody design services, special moieties with unique conjugation chemistries are engineered into antibody sequences. Besides, scientists at Creative Biolabs have abundant experience in performing lysine conjugation (amine reaction) and cysteine conjugation (thiol reactions) to create ADCs using these endogenous sites. “We are also expert in utilizing Tyrosine conjugation approaches as another innovated endogens site for ADC development,” said by a chief scientist and ADC project manager of Creative Biolabs.
Creative Biolabs scientists are committed to applying excellent science and technology to discover and develop efficient ADCs, and to offering world-leading custom linker design and drug-linker complex synthesis services to meet your specific demands for ADC developments based on the well-established “DrugLnk” organic synthesis platform. Our tailored services and high-quality products will contribute to your projects. Furthermore, with our expertise in and dedication to the antibody design platform and services for the conjugation chemistry, we will create the best customized ADCs for you.
About Creative Biolabs
Creative Biolabs is a global leading custom antibody provider. Its advanced antibody production platforms and highly professional experts allow the company to provide you with diverse ADC services to meet your different demands at the lowest cost level in the industry.
Company Name: Creative Biolabs
Contact Person: Bella Smith
Email: Send Email
Address:45-1 Ramsey Road
State: New York
Country: United States